Symposium NGS 2016
October 25, 2016
‘Next generation sequencing’ technologie in routine analyse binnen onze gezondheidszorg
Related documents
Introductie NL ● M. Van Den Bulcke, WIV-ISP- Commission Personalized Medicine (EN) ● M. Van Den Bulcke, WIV-ISP
- Platform CRM - TMC: a link procedure for companion reimbursement (EN) ● A. Waeytens, RIZIV-INAMI
- Guidelines ‘NGS in (hemato-)oncology' NGS genepanel testing (EN) ● A. Hébrant, WIV-ISP
- Benchmarking trial and EQA NGS in (hemato-)oncology (EN) ● V. Ghislain, WIV-ISP
- Patient participation: Focus group (EN) ● K. Moens, WIV-ISP
- Healthdata Datamanagement for NGS (EN) ● J. Van Bussel, WIV-ISP
- Accreditation of NGS within ISO 15189 (EN) ● E. Van Rossen, SPF Economie
- "Precision": Bringing innovation to the patient (EN) ● J. De Grève, Vrije Universiteit Brussel, Bruxelles, Belgique
- JARC: Joint Action Rare cancers (EN) ● A. Trama, Instituto Nationale di Tumori, Milan, Italie
- Impact on current and future cancer immunotherapies (EN) ● K. Vermaelen, UGent, Gand, Belgique
- Liquid biopsies (EN) ● S. Tejpar, KU Leuven, Louvain, Belgique
- NGS for oncogenetics (EN) ● M. Abramowicz, Université Libre de Bruxelles, Bruxelles, Belgique
- Comprehensive Genomic Profiling with FMI - bringing value to patients (EN) ● V. Natarajan, Foundation Medicine, Europe